1. No category

A COMPREHENSIVE INTELLIGENCE REPORT ON
ONCOLOGY
2013
DRUG
FUNDING
Sample Pages
EQUITY
321 Active Venture Capital Firm Profiles
502 Oncology Company Funding Details
947 Venture Partners Professional Profiles
3000 + Funding Round/Series Details
Oncology
Focused
FINANCE
PARTNER
Disclaimer
At the time of creation of this report, all information present herein was known to be true and accurate, to the best
knowledge of creators. HH BioTechnologies accepts no liability whatsoever for any loss or damage resulting
from errors, inaccuracies or omissions affecting any part of the publication. All information is provided without
warranty, and HH BioTechnologies makes no representation of warranty of any kind as to the accuracy or completeness of any information hereto contained.
978-81-926399-1-8
ISBN 978-81-926399-1-8
© September 2013 by HH BioTechnologies Pvt. Ltd. All rights reserved.
All information contained in this publication is copyrighted in the name of HH BioTechnologies Pvt. Ltd.,
and no part of this publication may be reproduced, resold, redistributed, stored in a retrieval system, or
transmitted in any form or by any means—electronic, mechanical, photocopying, scanning, or otherwise—
without prior written permission of the publisher.
Permissions may be sought directly from HH Biotechnologies’ through an email at [email protected]
ONCOLOGY DRUG FUNDING 2013
Content
4 - 13
Foreword
List of Figures
List of Tables
List of Investors
Executive Summary
Section A: Investor Firms - Infographics & Tables
14 - 25
Global Distribution of 321 Investor Firms, having Oncology Companies in their
Investment portfolio, on the basis of
• Geographic Location (U.S.A, Europe, Canada and Rest of the World)
• Area of Focus (Healthcare, Lifescience and Diversified)
• Fund Type (Angel Investor, Venture Capital and Private Equity)
• Fund/Assets under Management
Oncology Drug Funding Infographics – Europe (88 Investor Firms)
Investor coverage - Germany, UK, France, Switzerland, Netherland, Norway, Sweden, Denmark, Belgium,
Finland, Ireland, Spain.
Oncology Drug Funding Infographics – Asia (21 Investor Firms)
Investor coverage – Isreal, Japan, China, Taiwan, Singapore, Malaysia, Russia.
Oncology Drug Funding Infographics – United States of America (203 Investor Firms)
Investor coverage from all major States including California, Massachusetts, New York, North Carolina,
New Jersey, Washington, Connecticut, Illinois, Pennsylvania, Texas etc.
OmicsX - Intelligent BioSolutions
5
ONCOLOGY DRUG FUNDING 2013
Section B
Portfolio Companies- Infographics & Tables
26 - 58
Global Distribution of 449 Oncology Companies receiving various series of
funding in past 10 years from 321 Investor Firms.
• Global Distribution of Active Portfolio Oncology Companies in last 10 years. (296 companies)
• Global Distribution of Exit Portfolio Oncology Companies through IPOs/M&A activities in last 10
years. (153 companies)
Country wise Distribution of Investors and their 152 Portfolio Companies in
Europe and Asia.
State wise Distribution of Investor Firms and their 282 Portfolio Companies in USA.
Section C
Investor Profiles
59 - 561
Individual Profile of 321 Oncology focused Investor Firms.
Each Profile contains:• Investor Firm short description and its funding interests, countries of operations, past notable investments in oncology etc.
• Firm Logo, contact details, total investment portfolio, oncology investment portfolio, Fund size, assets
under management, ownership etc.
• Key Management Profiles of selected oncology focused Venture Partners with short description and
their contribution as venture partner, with email ID and link to their professional LinkedIn profile.
• Tables with funding series details in Exit and Active oncology companies, present in their portfolio
with co-investors names.
Appendix
562 - 569
Appendix A: Country Wise Investor Firms - List
Appendix B: List of Investor Firms - Funds Type (Angel Investor, Venture Capital & Private Equity).
Appendix C: List of Investor Firms - Funds Under Management.
6
OmicsX - Intelligent BioSolutions
ONCOLOGY DRUG FUNDING 2013
List of Figures
15 A.1
15 A.2
15 A.3
15 A.4
15 A.5
16 A.6
16 A.7
16 A.8
17 A.9
27 B.1
27 B.2
27 B.3
27 B.4
28 B.5
28 B.6
28 B.7
29 B.8
29 B.9
29 B.10
Figure
Global Distribution of 321 Investor Firms, with Oncology
Companies in their Investment portfolio.
Figure
Division of 321 Investor Firms, on the basis of Area of Focus.
(Healthcare, LifeScience Vs Diversified Investors)
Figure
Division of 321 Investor Firms on the basis of Fund Type.
(Angel Investor, Venture Capital Vs Private Equity)
Figure
Global Division of 321 Investor Firms on the basis of Funds under
Management.
Figure
Distribution of 110 Active Oncology focused Investor Firms in
Europe and Asia.
Figure
Country wise distribution of 88 Investor Firms in Europe on the
basis on funds under management.
Figure
Country wise distribution of 21 Investor Firms in Asia on the basis
on funds under management.
Figure
Distribution of 203 Active Oncology focused Investor Firms in
United States of America.
Figure
U.S Top 10 States with highest number of oncology supporting
Investor Firms.
Figure
Global Distribution of 449 companies receiving various rounds of
funding in past 10 years from 321 Investor Firms.
Figure
Global Division of Active Oncology Drug/Device/Diagnostics
Companies. (Active Portfolio - Last 10 years).
Figure
Global Division of Exit Oncology Drug/Device/Diagnostics
Companies. (Exit Portfolio - Last 10 years).
Figure
Global Division of Exit Company Portfolio.
(IPO, Mergers/Acquisitions or other routes).
Figure
Country wise Distribution of Investors and their 152 Portfolio
Companies in Europe and Asia.
Figure
Total Investor Firms Vs. their Active Portfolio Companies & Exit
Companies in Europe.
Figure
Total Investor Firms Vs. their Active Portfolio Companies & Exit
Companies in Asia.
Figure
State wise Distribution of Investors and their 282 Portfolio
Companies in USA.
Figure
Total Investor Firms Vs. their Active Portfolio Companies & Exit
Companies in USA.
Figure
Total Investor Firms Vs. their Active Portfolio Companies & Exit
Companies in California.
OmicsX - Intelligent BioSolutions
7
ONCOLOGY DRUG FUNDING 2013
List of Tables
Table
15 A.1
Investment Summary of 321 Investor Firms; Investment Focus,
Funds under Management, Investment Range with Active
Investment Portfolio (Oncology Companies Vs. Other Companies).
Table
30 B.1
Funding Series/Rounds Details and Co-Investors Summary of
Active Oncology Companies. (Companies Name, Therapeutic
Area, Oncology Pipeline, Key Technology, Collaborations, Series
A-E Details with Co-Investor Names)
49 B.2
Funding Series/Rounds Details and Co-Investors Summary of Exit
Oncology Companies. (Companies Name, Therapeutic Area, Exit
Year, Exit Strategy, Exit Value, Series A-E Details with Co-Investor
Names)
Table
8
OmicsX - Intelligent BioSolutions
ONCOLOGY DRUG FUNDING 2013
Table A.1: Investment Summary of 321 Investor Firms.
Funds Name
Investment Focus
Angel Early
Mid
3i Group plc
Late

Fund under
Management
Investment
Preference
Investment
Range
5000+
Worldwide
-
in Mn USD
Fund
Focused
Active Portfolio
Total Comp
Oncology Comp
Diversified
101
1
-
Life Science
31
4
in Mn USD
5AM Ventures


101 - 500
USA, Europe
Aberdare Ventures


101 - 500
USA
1 - 15
Healthcare
29
1
Abingworth LLP


1001 - 5000
Worldwide
20 - 80
Health Care
100+
1
ABS Ventures


1 - 100
USA
5 - 15
Diversified
60+
1
5000+
USA
5 - 20
Diversified
157
3
1001 - 5000
USA
-
Diversified
75
4
Adams Street Partners, LLC
Advanced Technology Ventures




Advantage Capital Partners


1001 - 5000
USA
0.5 - 10
Diversified
146
2
Advent Venture Partners


201 - 1000
USA, Europe
8 - 25
Diversified
51
7*
Aescap Venture

101 - 500
Europe
0.5 - 7
Biomedical
12
4

1 - 100
Europe
-
Life Science
6
5

1000 - 5000
USA
20 - 50
Healthcare
62
3

1 - 100
USA, Europe
-
Healthcare
11
1
101 - 500
USA
0.5 - 5
Diversified
30
1
501 - 1000
USA
1-5
Diversified
31
1
1001 - 5000
USA, Europe
-
Diversified
65
8
1 - 100
USA, Europe
1 - 10
Biotechnology
12
4
Aglaia Biomedical Ventures B.V

Aisling Capital
Alafi Capital Company LLC

Alliance Technology Ventures

Alloy Ventures

Alta Partners

Amgen Ventures

Anthem Capital Management


1 - 100
USA
1-5
Diversified
7
1
Aperture Venture Partners, LLC


501 - 1000
USA, Europe
1-4
Healthcare
6
1
Apjohn Ventures Fund

1 - 100
USA
0.5 - 2
Life Science
9
2
Apple Tree Partners


101 - 500
USA
-
Life Science
4
2
Apposite Capital LLP


101 - 500
USA, Europe
5 - 15
Healthcare
9
4
Aravis SA


101 - 500
Worldwide
1 - 10
Diversified
15
3
Arboretum Ventures


101 - 500
USA
3-7
Healthcare
20
1
ARCH Venture Partners


1001 - 5000
USA
-
Diversified
30
11
Arcus Ventures


101 - 500
USA
-
Life Science
8
3
Ascension Health Ventures


501 - 1000
USA
10 - 15
Healthcare
21
1

1 - 100
Worldwide
Biotechnology
16
5
1 - 100
USA
1-5
Diversified
23
1
Astellas Venture Management




-
Athenian Venture Partners

Atlas Venture


1001 - 5000
USA, Europe
0.5 - 5
Diversified
66
2
Auriga Partners


101 - 500
Worldwide
1-5
Diversified
37
2
Aurora Funds


101 - 500
USA
0.05 - 2.5
Diversified
23
2
Aurum Ventures MKI


1 - 100
Asia
Up to 10
Diversified
11
1
Avalon Ventures


101 - 500
USA
-
Diversified
55
5
Avlar BioVentures Ltd

101 - 500
Europe
-
Life Science
10
2
AXA Private Equity



5000+
Worldwide
-
Diversified
85
3
Bain Capital Ventures



1001 - 5000
USA
0.1 - 50
Diversified
65
1
Baird Capital



1001 - 5000
Worldwide
1 - 10
Diversified
55
3

101- 500
USA
2-5
Diversified
12
1
Ballast Point Ventures
Bay City Capital LLC


1001 - 5000
Worldwide
-
Life Science
25
4
Bayern Kapital GmbH


101 - 500
Europe
-
Diversified
20+
3
*
Oncology Exit Company
OmicsX - Intelligent BioSolutions
18
ONCOLOGY DRUG FUNDING 2013
Table B.1: Funding Series Details and Co-Investors Summary of Active Portfolio Oncology Companies.
Company
Therapeutic Area
Focus Area
4-Antibody AG
Oncology, Infectious,
Autoimmune,
Inflammatory Diseases
Treatment
Aarden
Pharmaceuticals
Oncology, Infectious,
Autoimmune,
Metabolic Diseases
Treatment
Acacia Pharma
Oncology
Supportive Care
Oncology Pipeline
Undisclosed (discovery)
Key Technology
Platform
Retrocyte Display®
Collaboration
Boehringer Ingelheim
Evotec AG
Human Genome
Sciences
Recepta Biopharma
Series A
Series D
Series E
Series F
NA
Elevate Ventures
[0.5 Mn/2009]
APD421 (clinical)
APD403 (clinical)
APD515 (clinical)
APD209 (clinical)
Gilde Healthcare,
Lundbeckfond Ventures
[10 Mn USD/2011]
Advanced Technology,
Avalon Ventures,
Flagship Ventures,
Polaris Venture,
Sutter Hill Ventures
Venrock
[25 Mn USD/2004]
Oncology,
Hematologic,
Mucoskeletal Disorders
Treatment
Dalantercept/ACE-041 (clinical)
Acerta Pharma
Oncology,
Autoimmune Diseases
Treatment
Undisclosed (discovery)
BioGeneration Ventures,
Life Sciences & Health Fund
[Undisclosed/2013]
ACT Biotech
Oncology
Treatment
Telatinib/BAY 57-9352 (clinical)
ACTB1003 (clinical)
ACTB1010 (IND)
ACTB1011 (preclinical)
NGN Capital
[24 Mn USD/2008]
Actinobac Biomed
Oncology,
Autoimmune Diseases
Treatment
Leukothera™
Acylin
Therapeutics
Oncology, Metabolic,
Neurodegeneartion
Disorders
Treatment
Aduro Biotech
Cancer,
Infectious Diseases
Treatment
CRS-207 (clinical)
ADU-623 (Preclinical)
Lm Prostate (Preclinical)
Lm Melanoma (Preclinical)
STINGVAX (Discovery)
Listeria
monocytogenes
Celgene Corp,
Shire plc,
Alkermes
Diagnostics
RNAscope HPV HNC (clinical)
RNAscope HPV CC (clinical)
RNAscope MELA (clinical)
RNAscope LCR (discovery)
RNAscope HER2 (discovery)
CTCscope (discovery)
RNAscope®
Advanced Technology,
Avalon Ventures,
Flagship Ventures,
Polaris Venture,
Sutter Hill Ventures,
Venrock,
OrbiMed Advisors
[30 Mn USD/2006]
Advanced Technology,
Avalon Ventures,
Flagship Ventures,
Polaris Venture,
Sutter Hill Ventures,
Venrock, OrbiMed Advisors, Bessemer Venture
[31 Mn USD/2007]
Advanced Technology,
Avalon Ventures,
Flagship Ventures,
Polaris Venture,
Sutter Hill Ventures,
Venrock, OrbiMed,
Bessemer Venture
[30 Mn USD/2011]
Foundation
Venture Capital
[0.6 Mn/2012]
ARCH Venture Partners,
OVP Venture Partners ,
WRF Capital
[4.4 Mn USD/2011]
Lysine protein acetylation
Morningside Group
[19.2 Mn USD/2011]
Advanced
Cell Diagnostics
Oncology
Aerpio
Therapeutics
Oncology,
Retinopathy,
Inflammatory Diseases
Treatment
AKB-9089 (discovery)
Affimed
Therapeutics
Oncology,
Inflammatory Diseases
Treatment
AFM-13 (clinical)
AFM-11 (preclinical)
AFM-12 (preclinical)
AFM-20 (discovery)
Agendia BV
Oncology
Diagnostics
Symphony™ Breast Cancer Suite
(MammaPrint®, BluePrint™,
TargetPrint® and TheraPrint®)
(approved) ColoPrint® (clinical)
AstraZeneca,
Agilent Technologies,
Agios
Pharmaceuticals
Oncology,
Genetic Diseases
Treatment
Undisclosed (discovery)
Celgene Corporation
OmicsX - Intelligent BioSolutions
Series C
Advent Venture,
BioMed Partners ,
Grazia Equity,
Life Sciences Partners
[18.5 Mn USD/2007]
Acceleron Pharma
30
Series B
Morningside Group
[5.4 Mn USD/2009]
Morningside Group
[12 Mn USD/2012]
AgeChem Ventures,
Athenian Venture Partners,
Kearny Venture Partners,
Novartis Venture Funds,
Triathlon Medical Ventures,
[27 Mn USD/2012]
BioMedPartners,
Life Sciences Partners,
Novo Nordisk Biotech
[45 Mn USD/2008]
BioMedPartners,
Life Sciences Partners,
Novo Nordisk Biotech,
OrbiMed Advisors
[26.3 Mn USD/2010]
BioMedPartners
Life Sciences Partners,
Novo Nordisk Biotech,
OrbiMed Advisors
[20.4 Mn USD/2012]
AXA Private Equity,
Gilde Healthcare,
Global Life Science
[Undisclosed/2004]
AXA Private Equity,
Gilde Healthcare,
Global Life Science
[Undisclosed/2005]
AXA Private Equity,
Gilde Healthcare Partners,
Global Life Science
[Undisclosed/2006]
AXA Private Equity,
Gilde Healthcare,
Global Life Science
[35 Mn USD/2007]
ARCH Venture Partners,
Flagship Ventures,
Third Rock Ventures
[33 Mn USD/2008]
ARCH Venture Partners,
Flagship Ventures,
Third Rock Ventures
[8.8 Mn USD/2010]
ARCH Venture Partners,
Flagship Ventures,
Third Rock Ventures
[78 Mn USD/2011]
TandAb®
AXA Private Equity,
Gilde Healthcare,
Global Life Science
[23 Mn USD/2009]
AXA Private,
Gilde Healthcare,
Global Life
Science
[65 Mn/2012]
ONCOLOGY DRUG FUNDING 2013
Table B.2: Funding Series Details and Co-Investors Summary of Exit Portfolio Oncology Companies.
Company
Therapeutic Area
Focus Area
Exit Year
Exit Strategy
Value (Mn Usd)
Series A
Series B
3-Dimensional
Pharmaceuticals
Oncology, Inflammation,
Metabolic and
Cardiovascular Diseases
Treatment
2003
Acquired by J&J
Ablynx
Oncology, Inflammation,
Hematology, and
Pulmonary Diseases
Treatment
2007
IPO
GIMV
GIMV
AcelRx
Pain
Treatment
2011
IPO
Pinnacle Ventures,
Skyline Ventures,
Three Arch Partners
Pinnacle Ventures,
Skyline Ventures,
Three Arch Partners
Adherex
Technologies
Oncology
Treatment
2007
IPO
Atlas Venture,
Flagship Ventures,
HBM Healthcare,
Polaris Venture
Atlas Venture,
Flagship Ventures,
HBM Healthcare,
Polaris Venture,
Venrock
Series C
Series D
$88
Series E
Series F
NA*
Rho Ventures
GIMV
VIMAC Ventures
Atlas Venture,
Flagship Ventures,
HBM Healthcare,
Polaris Venture,
Venrock
Adnexus
Therapeutics
Oncology, and
Immunology
Treatment
2007
Acquired by BMS
ADVENTRX
Pharmaceuticals
Oncology, and
Hematology
Treatment
2000
IPO
Tech Coast Angels
Affitech
Oncology, and
Inflammatory Diseases
Treatment
2010
IPO
Teknoinvest
Agennix
Oncology, and Diabetes
complications
Treatment
2009
IPO
Agensys
Oncology
Treatment
2007
Acquired by Astellas
Agenus
Oncology, and Infectious
Diseases
Treatment
2000
IPO
Alchemia Limited
Oncology
Treatment
2003
IPO
$505
Dievini Hopp
Alta Partners,
HBM Healthcare,
Nextech Invest
$537
Flagship
Ventures
CM Capital Investments
Harbert Venture Partners,
Intersouth Partners,
Piedmont Angel Network,
Tall Oaks Capital Partners
Aldagen
Oncology, and Cardiovascular Disorders
Treatment
2012
Acquired by Cytomedix
Alerion
Biomedical
Oncology, Cardiovascular,
and CNS Disorders
Imaging
2006
Acquired by ART
Advanced
Research Undisclosed
Technologies
Algeta
Oncology
Treatment
2007
IPO
Advent Venture Partners,
Birk Venture,
HealthCap
Allos
Therapeutics
Oncology
Treatment
2000
IPO
Abingworth,
Aisling Capital,
New Leaf Venture,
Sequel Venture Partners,
SV Life Sciences
Abingworth,
Aisling Capital,
New Leaf Venture,
Sequel Venture Partners,
SV Life Sciences
Alnylam
Pharmaceuticals
Oncology, Bleeding
Disorders, Cardiovascular
Disorder, and others
Treatment
2004
IPO
Abingworth,
Atlas Venture,
Cardinal Partners,
Polaris Venture,
Roche Venture
Abingworth,
ARCH Venture Partners,
Atlas Venture,
Cardinal Partners,
Polaris Venture,
Roche Venture
Altiris
Therapeutics
Oncology
Treatment
2005
Acquired by Celldex
Research
Undisclosed
BioAdvance
Anesta
Corporation
Cancer Pain
Treatment
2000
Acquired by Cephalon
$444
Flagship Ventures
AnGes MG
Oncology, CNS, Cardiovascular Disorders, and
others
Treatment
2002
IPO
Mitsubishi UFJ Capital Co
Antisoma
Oncology
Treatment
2005
IPO
CDIB BioScience,
HealthCare Ventures,
Roche Venture
Aposense
Oncology
Molecular
Imaging &
Treatment
2010
IPO
$40
Aurora Funds,
Intersouth Partners
Research Corporation
Technologies
Clal Biotechnology,
MediTech Partners
* Key Investors
OmicsX - Intelligent BioSolutions
49
ONCOLOGY DRUG FUNDING 2013
ABOUT FUND
»» Adams Street Partner is a private equity investment, employee-owned private equity firm and is one of the largest
managers of private equity for institutional investors.
»» Adams Street Partners’ Direct Team invests $5-20 million
in companies seeking venture capital or growth equity to
accelerate their businesses or to provide partial liquidity
for existing shareholders. Each year roughly 10 new companies are provided funds through this channel.
GENERAL INFORMATION
Investor Name: Adams Street Partners, LLC
Managed By: NA
Founded in: 1972
Focus: Diversified
Fund Type: Private Equity
Total Portfolio Companies: 157
Active Cancer Focused Companies in Portfolio: 3
Fund under Management: $22,000 Mn USD
Address: One North Wacker Drive, Suite 2200 Chicago,
Illinois 60606-2823 U.S.A
URL: www.adamsstreetpartners.com
Email: [email protected]
Ownership: Private
Exchange: NA
Ticker: NA Market Capitalization: NA
»» Firm invest into fast-growing and late stage companies
in the Technology and Life Sciences (Biopharmaceuticals/
Medical devices) sectors.
»» The firm seeks to invest in companies predominantly that
are based in the United States.
»» It invests in companies that have received prior financing
from early-stage venture firms and are seeking additional
capital to fund product development & commercialization.
MANAGEMENT PROFILES
Terry Gould
Head of Direct Investments
[email protected]
Michael Lynn
Partner
[email protected]
Linked
profile
Thomas Bremner
Principal
[email protected]
Linked
profile
Terry Gould joined in 1994 and is the Head of Direct Investments for medical device and
biopharma sectors. He sits on the Boards of Directors of Incline Therapeutics, Neuraltus,
Proteus Digital and OncoMed. He is responsible for several other successful investments:
CombiChem, Heartport, INC Research, Jazz Pharma, NxStage, Revivant, Spinal Dynamics
and Vivant Medical. He did BA from Dartmouth College & MBA from Stanford University.
Assistant: Victoria Long e-mail: [email protected] Linked profile
Michael Lynn joined in 2007 and is responsible for sourcing and screening private equity
investments in the medical device and biopharmaceutical sectors. Mike serves on the
Boards of Directors of Luminous Medical, MyHealthTeams, Pivot Medical, PneumRx, Revascular, TriReme and USGI Medical and is a Board Observer at GlobeImmune. He did BA
from Carleton College and MD from UCLA School of Medicine.
Assistant: Nancy Thomsen e-mail: [email protected] Linked profile
Thomas Bremner joined Adams Street Partners in 2013 and is responsible for sourcing
and leading late stage venture and growth equity investments in the technology and
health care sectors. He did BS from University of Dayton and MBA from University of
Chicago Booth School of Business.
Assistant: Kirsten Cimmarusti e-mail: [email protected] Linked profile
CURRENT PORTFOLIO COMPANIES
Company
Country
GlobeImmune
69
USA
Key Area
Drug discovery
& development
OmicsX - Intelligent BioSolutions
Funding (in USD)
$38.4 Mn (Series B)
$41.2 Mn (Series C)
$10 Mn (Series D)
$17.5 Mn (Series E)
Year
Jan 2006
Sep 2007
May 2009
Jan 2010
Description
Co-Investor
Biopharma company developing therapeutic vaccines for
the treatment of cancer and
infectious diseases.
HealthCare Ventures, Biogen Idec,
Lilly Ventures, Celgene,
Morgenthaler Ventures,
Sequel Venture, Genentech,
Medica Venture ,
Partners Healthcare,
GC&H Investments, CIDC,
PAC-LINK Bio Venture,
Yasuda Enterprise Development,
Wexford Capital, BSI SA,
Mellon Family Investment Company,
Richard King Mellon Foundation,
Eminent Venture Capital,
Boston Life Science Venture,
WRF Capital,
Generali Financial Holding
ONCOLOGY DRUG FUNDING 2013
Company
Light
Sciences
Oncology
OncoMed
Pharmaceuticals
Country
USA
USA
Key Area
Drug discovery
& development
Funding (in USD)
$67 Mn (Series A)
$30 Mn (Series B)
$40.1 Mn (Series C)
Year
Description
Co-Investor
Dec 2005
Jul 2007
Jul 2008
Engaged in developing lightactivated drug products for the
treatment of cancer.
Essex Woodlands Health Ventures,
Johnson and Johnson, Novo A/S,
China Development Industrial Bank,
Larkspur Capital Corporation,
Scandinavian Life Science Venture,
New Science Ventures,
Lehman Brothers, Burrill & Co.,
Deephaven Capital Management,
The Malaysian Life Sciences Capital Fund
US Venture Partners,
Latterell Venture Partners,
Vertical Group, Delphi Ventures,
Morgenthaler Ventures,
DeNovo Ventures,
Bay Partners
Drug discovery
& development
$169 Mn (Series B)
Dec 2008
Clinical stage company developing monoclonal antibodies
targeting cancer stem cells for
the treatment of cancer.
Key Area
Funding (in USD)
Year
Description
EXIT COMPANIES
Company
Zalicus
(formerly
CombinatoRx)
Vivant
Medical
Country
USA
USA
Drug discovery
&development
Medical device
$40 Mn (Series B)
$30 Mn (Series C)
$19 Mn
(total funding)
Co-Investor
2006
(IPO)
A biopharma company developing therapies for the treatment
of pain and immuno-inflammatory diseases
Boston Millennia Partners,
Easton Capital,
Yasuda Enterprise Development,
Global Life Science Ventures,
Canaan Partners, Flagship Ventures,
TL Ventures, Novartis BioVentures,
Global Life Science Ventures,
POSCO BioVentures,
CDIB BioScience Ventures,
BioVentures Investor
2005
(acquired
by Valleylab)
Develops microwave ablation
technology for the minimally invasive treatment of benign and
cancerous soft tissue tumors
California Technology Ventures,
Johnson & Johnson,
Pacific Venture Group,
Three Arch Partners
OmicsX - Intelligent BioSolutions
70
ONCOLOGY DRUG FUNDING 2013
ABOUT FUND
»» Lundbeckfond Ventures, wholly owned by the Lundbeck
Foundation, is a venture capital firm specializing in early
stage investments in life science companies.
»» It make investments within life science sector, focusing
on pharmaceuticals, biopharmaceuticals, medtech and
diagnostics companies.
GENERAL INFORMATION
Investor Name: Lundbeckfond Ventures
Managed By: Lundbeckfond Ventures
Founded in: 2009
Focus: Life Sciences
Fund Type: Venture Capital
Current Total Portfolio Companies: 12
Active Cancer Focused Companies in Portfolio: 4
Fund under Management: $1 - $100 Mn USD
Address: Vestagervej 17
DK-2900 Hellerup, Denmark
URL: www.lundbeckfondventures.com
Email: [email protected]
Ownership: Private
Exchange: NA
Ticker: NA Market Capitalization: NA
»» Lundbeckfond Ventures invests up to € 50 Mn in companies primarily located in the Northern Europe.
»» Its present portfolio consists of 12 companies in the active mode of investment from various therapeutic areas.
MANAGEMENT PROFILES
Mette Kirstine Agger is Managing Partner of Lundbeckfond Ventures. She was previously CoFounder and CEO of 7TM Pharma and has a broad international experience within biotech/life
science covering business development and licensing, management and financing. Prior, Mette
was part of the management team of NeuroSearch responsible for business development and
licensing. She started her carrier as Patent Agent. Mette has been appointed to numerous board
positions both in private and public companies including Allocure, Psioxus and Veloxis. She is an
M.B.A and is graduated as Biologist from the University of Copenhagen.
Mette Kirstine Agger
Managing Partner
[email protected]
Linked
profile
Johan Kördel is Senior Partner of Lundbeckfond Ventures. He was previously Co-Founder and
CEO of Sound Biotech and Co-Founder and Senior VP of Research and Business Development
of Biovitrum. Prior to these positions he worked almost a decade in Pharmacia. Johan has cofounded other biotech companies and been appointed to numerous board positions both in
private and public companies. Presently, he is a board member of Acacia Pharma, Celladon,
Enterome, River Vision and Syntaxin. He is an associate professor in Physical Chemistry at the
University of Lund, Sweden.
Johan Kördel
Senior Partner
[email protected]
Linked
profile
CURRENT PORTFOLIO COMPANIES
Company
Country
Key Area
Funding (in USD)
Year
Description
Co-Investor
Acacia
Pharma
U.K
Cancer
management
$10 Mn (Series A)
Mar 2011
Pharmaceutical company specialising
in the development of drugs for cancer
supportive care.
Glide Healthcare
PsiOxus
Therapeutics
U.K
Drug discovery
& development
$34 Mn (Series B)
Jul 2012
Development-stage biotech company,
developing therapeutic vaccines for the Imperial Innovations Group,
treatment of cancer and its related con- Invesco Perpetual, SR One
ditions.
Diagnostics
$11.6 Mn
(Undisclosed)
Apr 2013
Medical device company that develops
and manufactures imaging systems focusing on the detection of cancerous
and pre-cancerous lesions.
Albion Ventures, NBGI,
the Scottish Investment Bank
Nov 2010
Biopharma company developing biologic drugs (Targeted Secretion Inhibitors) for the treatment of various disorders, including cancer.
Seventure Partners, Ipsen,
Abingworth, SR One,
Life Science Partners,
Johnson & Johnson Development
Corporation,
Quest for Growth,
DySIS
Medical
Syntaxin
323
UK
UK
Drug discovery
& development
$27 Mn (Series C)
OmicsX - Intelligent BioSolutions
ONCOLOGY DRUG FUNDING 2013
ABOUT FUND
»» Telegraph Hill Partners is a private equity firm specializing
in late venture, growth equity and management buyouts.
»» Investment targets commercial companies within the
healthcare sector, including life science technologies,
medical devices, chemistry and reagent suppliers, healthcare services and information management.
GENERAL INFORMATION
Investor Name: Telegraph Hill Partners
Managed By: Telegraph Hill Partners
Founded in: 1992
Focus: Life Sciences & Healthcare
Fund Type: Private Equity
Total Portfolio Companies: 23
Active Cancer Focused Companies in Portfolio: 2
Fund under Management: $100 - $500 Mn USD
Address: 360 Post Street, Suite 601
San Francisco, CA 94108, U.S.A
URL: www.thpartners.net
Email: [email protected]
Ownership: Private
Exchange: NA
Ticker: NA Market Capitalization: NA
»» Its investments are carried through Telegraph Hill Partners, Telegraph Hill Partners II (a $150 Mn USD later stage
venture capital fund) and Telegraph Hill Partners III (a
venture capital fund investing in small, privately-held life
science, medical technology and healthcare infrastructure
companies).
»» The firm prefers to invest in companies primarily based in
the US.
»» Telegraph Hill Partners seeks to exit its investments in
three to five years via an industry sale or an initial public
offering.
MANAGEMENT PROFILES
Matthew Mackowski is Chairman and Managing Director of Telegraph Hill Partners. He began his venture capital career with Citicorp Venture Capital, where he was VP and a member of the investment
J. Matthew Mackowski executive committee. He later joined Robertson, Stephens & Co. and was partner and Chairman of
Chairman, MD
the Venture Capital Group. He formed Mackowski & Shepler, an investment partnership focused on
[email protected]
developing life science and medical technology companies. Matt has represented THP on the boards
of Kinetikos Medical, Ambion, Aurora Discovery, Interface Associates, Asuragen, Althea, AltheaDx and
MedPricer. He received a B.A. from Duke University and an M.B.A. from The Wharton School.
Robert G. Shepler
Managing Director
[email protected]
Linked
profile
Deval A. Lashkari
Partner
[email protected]
Linked
profile
Robert Shepler is Managing Director of Telegraph Hill Partners. He has been a corporate transactions specialist and investor since 1978, with a focus on strategic M&A transactions. During his
career, he has served on numerous company boards and completed over 150 M&A and financing
transactions. Prior to joining THP, he worked with Merrill Lynch & Co. as an Officer in their San
Francisco corporate finance office. Robert has represented THP on the boards of Kinetikos Medical, AcroMetrix, Aurora Discovery, Applied Precision, RareCyte, LDR Spine, Estech and VidaCare.
He received a B.A. from Duke University and an M.B.A. from New York University.
Dr. Deval Lashkari is Partner of THP. He has worked in the life sciences area since 1988 on developing
and commercializing novel technologies. He gained corporate and business development experience
through senior management positions in a number of life science companies. He was a founding
Research Director at Synteni, where he became Director of Product Development. Dr. Deval has represented THP on the Boards of AcroMetrix, Althea, AltheaDx, Applied Precision, Aurora Discovery,
NEXUS Biosystems, RareCyte, and SwitchGear Genomics. He was Board Observer of Dharmacon.
He received a B.A. from the University of California, Berkeley and a Ph.D. from Stanford University.
CURRENT PORTFOLIO COMPANIES
Company
Asuragen
RareCyte
Country
Key Area
Funding (in USD)
Year
Description
Co-Investor
USA
Molecular
Diagnostics
$49 Mn (Series A)
$18.5 Mn (Series B)
Jun 2007
Dec 2007
Molecular diagnostics company
focused on oncology and companion diagnostics with special
capabilities in the area of mRNA
and miRNA.
Growth Capital Partners, PTV Sciences
Jul 2012
Life science research and diagnostic company focused on
characterizing and isolating rare
cells in the blood, in various
forms of cancer and infectious
disease.
-
USA
Molecular
Diagnostics
Undisclosed
(series A)
OmicsX - Intelligent BioSolutions
500
Order Form
YES, I WOULD LIKE TO PURCHASE NOW
Product Name: A Comprehensive Intelligence Report On - Oncology Drug Funding 2013
Product Type: Intelligence Report (570 pages)
Product Code: ODF2013
Single user price: $1495.00
Published by: HH Biotechnologies Pvt. Ltd.
Published in: September 2013
Online Purchases: Click Here
Payment
To pay by Credit Card (PayPal, Visa, MasterCard, American Express), please, click ‘BUY NOW’ button on repot page
http://omicsx.com/reports.html
If you want to order Corporate
License or Hard Copy, please,
contact our Customer Service:
[email protected]
Stay Legal: Terms &
Conditions
In placing an order you agree
not to hand-on or otherwise
communicate this report in
whole or part to any 3rd party
whatsoever by any means or
any access. You firstly pay for
report, then I provide it.
Our full terms and conditions
related to the sale of this
report please click here....
Sales Contact Numbers
USA
UK
Asia
+1 646 513 4433
+44 203 608 3536
+91 562 228 1122
Your Details: (Please use BLOCK CAPITALS)
Title: Dr
Mr
Ms
First Name:__________________________________________________
Last Name:___________________ Middle Name:____________________
Department:_________________________________________________
Position:_____________________________________________________
Company:____________________________________________________
Address:_____________________________________________________
___________________________________________________________
____________________________State/Province___________________
Country:_____________________Postcode/Zip:____________________
Tel:____________________________ Fax:_________________________
Fax back this form to
Mobile No:__________________________________________________
USA
Asia
Email:_______________________________________________________
+1 646 568 9962
+91 562 228 1099
Mail this completed
order form to:
HH Biotechnologies Pvt. Ltd.
2760,Link Road,
Nunhai Industrial Area,
Near Rambagh,
Agra-282006 India.
E-mail: [email protected]
Online: www.omicsx.com
Please sign below to confirm your order
Date: ___________
Signature______________________________________
(All orders must be signed by authorised signatory)